If you have been reading about GIP receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-10. Numbers and descriptions here follow the published literature rather than marketing material.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection |
| Solubility | Soluble in aqueous buffer | Lipophilic chain lowers pure-water solubility |
| Long-term storage | -20 degrees Celsius or lower | With desiccant, protected from light |
| Short-term storage | 2 to 8 degrees Celsius | For dissolved aliquots |
| Typical purity method | Reversed-phase HPLC | Ultraviolet detection, often with mass confirmation |
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
=== Category:EC 3.4 (act on peptide bonds - Peptidase) === Category:EC 3.4.11 Alanine aminopeptidase Category:EC 3.4.15 Angiotensin converting enzyme Category:EC 3.4.21 Serine protease Chymotrypsin (EC 3.4.21.1) Trypsin (EC 3.4.21.4) Thrombin (EC 3.4.21.5) Factor X (EC 3.4.21.6) Plasmin (EC 3.4.21.7) Acrosin (EC 3.4.21.10) Factor VII (EC 3.4.21.21) Factor IX (EC 3.4.21.22) Prolyl oligopeptidase (EC 3.4.21.26) Factor XI (EC 3.4.21.27) Elastase (EC 3.4.21.37) Factor XII (EC 3.4.21.38) Proteinase K (EC 3.4.21.64) Tissue plasminogen activator (EC 3.4.21.68) Protein C (EC 3.4.21.69) Category:EC 3.4.22 Separase (EC 3.4.22.49) Category:EC 3.4.23 Pepsin (EC 3.4.23.1) Rennet (EC 3.4.23.4) Renin (EC 3.4.23.15) Trypsinogen (EC 3.4.23.18) and (20/21/23/24/26) Plasmepsin (EC 3.4.23.39) Category:EC 3.4.24 Matrix metalloproteinase (EC 3.4.24.7) Category:EC 3.4.25 Metalloendopeptidase
Carrasco had previously been Castillo's Interior Minister during the Bellido cabinet. On 19 November, Presidential Secretary Bruno Pacheco resigned. Pacheco claimed to be innocent, and said he was resigning to stop the smear campaign against the president.
RSH + Cl–S–C(=O)–Cl → RS–S–C(=O)–Cl + HClThese reagents are useful for the derivatization of biological thiols. Methoxycarbonylsulfenyl chloride, a related reagent derived from the above chemistry, is used in solid-phase peptide synthesis for selective disulfide bond formation via conversion of the acetamidomethyl (Acm) cysteine protecting group to thiol-labile S-alkylsulfenyl thiocarbonate (carbomethylsulfenyl, Scm) protecting group.
== Treatment == Often, the symptoms of degenerative disc disease can be treated without surgery. One or a combination of treatments such as physical therapy, anti-inflammatory medications such as nonsteroidal anti-inflammatory drugs, traction, or epidural steroid injection can provide adequate relief of troubling symptoms. Surgery may be recommended if the conservative treatment options do not provide relief within two to three months for cervical or 6 months for lumbar symptoms. If leg or back pain limits normal activity, if there is weakness or numbness in the legs, if it is difficult to walk or stand, or if medication or physical therapy are ineffective, surgery may be necessary, most often spinal fusion. There are many surgical options for the treatment of degenerative disc disease, including anterior and posterior approaches. The most common surgical treatments include:
The most common side effects of benzodiazepines are related to their sedating and muscle-relaxing action. They include drowsiness, dizziness, and decreased alertness and concentration. Lack of coordination may result in falls and injuries, particularly in the elderly. Another result is impairment of driving skills and increased likelihood of road traffic accidents. Decreased libido and erection problems are a common side effect. Depression and disinhibition may emerge. Hypotension and suppressed breathing (hypoventilation) may be encountered with intravenous use. Less common side effects include nausea and changes in appetite, blurred vision, confusion, euphoria, depersonalization and nightmares. Cases of liver toxicity have been described but are very rare. The long-term effects of benzodiazepine use can include cognitive impairment as well as affective and behavioural problems. Feelings of turmoil, difficulty in thinking constructively, loss of sex drive, agoraphobia and social phobia, increasing anxiety and depression, loss of interest in leisure pursuits and interests, and an inability to experience or express feelings can also occur. Not everyone, however, experiences problems with long-term use. Additionally, an altered perception of self, environment and relationships may occur. A study published in 2020 found that long-term use of prescription benzodiazepines is associated with an increase in all-cause mortality among those age 65 or younger, but not those older than 65.
Sources: en.wikipedia.org
The indictment against Duterte, which was made public on September 22, 2025, accused him of involvement in the murders of 76 people between 2013 and 2018. Fifty-seven of the killings took place during his presidency, and the other 19 occurred during his third term as mayor of Davao City. On October 10, 2025, the ICC rejected a request from Duterte to be released from detention, arguing that he posed a risk of fleeing and would not be willing to return for trial, as well as presenting concerns about potential witness intimidation if he were granted freedom. On January 26, 2026, the ICC declared Duterte fit for trial, overruling efforts by his lawyers to have the charges dismissed on health grounds. Duterte waived his right to appear at any proceedings, with his lawyer Nicholas Kaufman stating that he was not mentally fit to follow the hearing. On April 23, 2026, the Pre-Trial Chamber of the ICC committed Duterte to trial. In May 2026, the ICC Pre-Trial Chamber I denied Duterte's appeal to dismiss the charges. That same month the Trial Chamber III of the ICC set the opening statements in Duterte's trial to begin on November 30, 2026. On September 3, 2026, his defense asked the ICC to verify digital evidence presented by the prosecution, saying that much of the material against Duterte had been taken from open-source and user-generated content from the internet.
== History == Glenmark was incorporated on 18 November 1977. It began producing generic drugs and active pharmaceutical ingredients for markets in India, Russia, and Africa, and went public on Indian stock exchanges in 1999. Glenn Saldanha, Gracias's son, became managing director in 2001 after working at Eli Lilly and Company and PricewaterhouseCoopers. Under his leadership the company expanded internationally; by 2008 it had become one of India's larger pharmaceutical manufacturers by sales volume, and in 2011 consolidated worldwide sales reached $778 million. That year Glenmark established its first North American manufacturing facility in Monroe, North Carolina. In the mid-2010s, Glenmark changed direction. The generic drug industry was seeing fewer patent expirations, and the company began developing proprietary medicines in oncology, dermatology, and respiratory treatments. It researched drugs internally and licensed them to larger pharmaceutical companies. By 2016, four Glenmark drugs were in clinical development. A respiratory treatment was licensed for commercialisation in North America and Japan, and a diabetes drug was licensed to Merck's German division. Sales that fiscal year were approximately ₹81 billion (about $1.25 billion), ranking it fourth among India's pharmaceutical manufacturers by revenue. Glenmark built a consumer healthcare business in India that included the antifungal Candid, launched in 1979, the respiratory medication Ascoril, and La Shield. It divested the intimate hygiene brand VWash to Hindustan Unilever in March 2020.
=== Protein evolution and origins of life === In addition to structural bioinformatics, Ben-Tal has worked on protein evolution and the emergence of protein architectures and functions. His laboratory describes this research as addressing how novel protein structures and functions arise during molecular evolution. To trace the evolutionary history of proteins, Ben-Tal, Rachel Kolodny of University of Haifa and coworkers searched among large representative sets of proteins for segments that are similar in sequence (and often also in structure). They presented the results as a similarity network, using a methodology that they tailor-made for this study, showing that many proteins share smaller segments with each other. For example, they observed the same amino acid both within a short theme shared by many proteins and within a longer theme shared only by few. Next, they searched for themes that appear in different sequence and structural contexts within proteins, calling these bridging themes. They found many bridging themes, with an average length of about 40 residues. Interestingly, only about half of these also share a similar structure; the different environment may have induced a conformational change. Some of the bridging themes bind ligands, which attests to their functional importance. Another testimony to the evolutionary importance of these themes is the fact that some of the most ancient protein folds (e.g. Rossmann, P-loop, and TIM-barrel) were found to share them. The bridging themes may offer hints to the emergence of earliest protein families.
Powdered milk is a common item in UN food aid supplies, fallout shelters, warehouses, and wherever fresh milk is not a viable option. It is frequently used in the manufacture of infant formula. Like other dry foods, it is considered nonperishable and is favored by survivalists, hikers, and others requiring nonperishable, easy-to-prepare food. It is widely used in many developing countries because of reduced transport and storage costs (reduced bulk and weight, no refrigerated vehicles). Because of its resemblance to cocaine and other drugs, powdered milk is sometimes used in filmmaking as a non-toxic prop that may be insufflated.
Glutathione S-transferase A1 is an enzyme that in humans is encoded by the GSTA1 gene. Cytosolic and membrane-bound forms of glutathione S-transferase are encoded by two distinct supergene families. These enzymes function in the detoxification of electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins and products of oxidative stress, by conjugation with glutathione. The genes encoding these enzymes are known to be highly polymorphic. These genetic variations can change an individual's susceptibility to carcinogens and toxins as well as affect the toxicity and efficacy of some drugs. At present, eight distinct classes of the soluble cytoplasmic mammalian glutathione S-transferases have been identified: alpha, kappa, mu, omega, pi, sigma, theta and zeta. This gene encodes a glutathione S-transferase belonging to the alpha class. The alpha class genes, located in a cluster mapped to chromosome 6, are the most abundantly expressed glutathione S-transferases in liver (hepatocytes) and kidney (proximal tubules). In addition to metabolizing bilirubin and certain anti-cancer drugs in the liver, the alpha class of these enzymes exhibit glutathione peroxidase activity, thereby protecting the cells from reactive oxygen species and the products of peroxidation.
Sources: en.wikipedia.org
==== MeSH E05.820.150 – breeding ==== MeSH E05.820.150.360 – estrus detection MeSH E05.820.150.370 – estrus synchronization MeSH E05.820.150.390 – hybridization, genetic MeSH E05.820.150.520 – inbreeding
==== Dihydropyrazine and pyrazine synthesis ==== Reaction of the lactam-derived enol phosphates 4 of 2,5-diketopiperazines with palladium catalyzed reactions (reduction, Suzuki and Stille cross-coupling reactions) enables the synthesis of a range of functionalised 1,4-dihydropyrazines 5 which can be aromatized to 1,4-pyrazines 6 in the presence of acid.
In general, drugs like suvomipic are only thought to have potential effectiveness for a given follicle if it is still intact, undamaged, and merely dormant. Hair follicles are known to undergo progressive damage from low-grade microinflammation and reduced blood flow in androgenic alopecia, resulting not only in dormancy but also in perifollicular fibrosis and associated follicular miniaturization. In addition, in more advanced or later-stage cases, there can be arrector pili muscle detachment and micro-scarring. These sequelae are thought to limit the potential for follicular regeneration.
Fibrosis, also known as fibrotic scarring, is the development of fibrous connective tissue in response to an injury. Fibrosis can be a normal connective tissue deposition or excessive tissue deposition caused by a disease. Repeated injuries, chronic inflammation and repair are susceptible to fibrosis, where an accidental excessive accumulation of extracellular matrix components, particularly collagen, is produced by fibroblasts, leading to the formation of a permanent fibrotic scar. In response to injury, this is called scarring, and if fibrosis arises from a single cell line, this is called a fibroma. Physiologically, fibrosis acts to deposit connective tissue, which can interfere with or totally inhibit the normal architecture and function of the underlying organ or tissue. Fibrosis can be used to describe the pathological state of excess deposition of fibrous tissue, as well as the process of connective tissue deposition in healing. Defined by the pathological accumulation of extracellular matrix (ECM) proteins, fibrosis results in scarring and thickening of the affected tissue — it is in essence a natural wound healing response which interferes with normal organ function.
Sources: en.wikipedia.org
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.
Lyophilised powder is generally held at minus twenty degrees Celsius or lower for long-term storage. Once dissolved, aliquots are kept at two to eight degrees Celsius for short periods and should not be repeatedly frozen and thawed.
Photo-oxidation can modify tryptophan, methionine, and tyrosine residues, altering the structure. Amber glass containers or foil wrapping are routine measures to reduce light exposure.
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.